Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nadunolimab + toripalimab
- Development stage
- Unknown
- Lead developer
- Cantargia
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nadunolimab + toripalimab is an investigational combination immunotherapy consisting of an anti-IL-1RAP monoclonal antibody (nadunolimab) and an anti-PD-1 monoclonal antibody (toripalimab). This combination is specifically being evaluated for the treatment of chemotherapy-refractory metastatic microsatellite stable (MSS) colorectal cancer, a population that typically shows poor response to single-agent checkpoint inhibitors. Nadunolimab targets the interleukin-1 receptor accessory protein (IL-1RAP), which is overexpressed on various cancer cells and immune cells, thereby inhibiting IL-1 signaling and potentially reducing tumor-promoting inflammation. Toripalimab blocks the PD-1 receptor on T-cells, preventing its interaction with PD-L1/PD-L2 and restoring the immune system's ability to recognize and attack tumor cells. By combining these two agents, the therapy aims to overcome the immunosuppressive environment typical of MSS colorectal cancer.
- Brand names
- Tuoyi
- Other names
- nadunolimab + toripalimab
02
Targets
IL1RAP (Interleukin 1 receptor accessory protein)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nadunolimab + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nadunolimab + toripalimab.